Health Care Professionals Log In

Proven healing and symptom control
for daytime and even NIGHTTIME
erosive GERD with PROTONIX*†

Welcome to the PROTONIX Web site for health care professionals—your online resource for clinical studies on PROTONIX, product information, patient education materials, and more. Here you'll find information on the serious effects of erosive gastroesphogeal reflux disease (GERD), the mechanism of action of PROTONIX, and data on healing and symptom relief.
PROTONIX 40mg
PROTONIX IV
Renew

* In a 12-month study of patients with healed erosive esophagitis treated with PROTONIX 40 mg, 94% of days were acid    regurgitation-free and 93% of nights were heartburn-free.

† In a study of patients with acute erosive esophagitis, 95% with grade 2 and 88% with grade 3 or 4 were healed at 8 weeks    (healing to grade 0 or 1 on the Hetzel-Dent scale).

‡ In a clinical study of 21 patients with ZES, acid output was reduced below 10 mEq/h in all patients.



PROTONIX InTouch

Get the facts about PROTONIX 40 mg through
interactive on-demand services and resources.
Start here (Medscape registration required)

Patient Assistance

The Wyeth Patient Assistance Program helps patients in need receive medications and get them in a timely manner. Find out more


Acrobat LogoThese documents are in PDF (portable document format). PDF files require Adobe® Reader®; click here to download this free program.

PROTONIX 40 mg Delayed-Release Tablets

Indications
  • PROTONIX Delayed-Release Tablets are indicated for the treatment and maintenance of healing of erosive esophagitis with associated GERD symptoms. Controlled studies did not extend beyond 12 months.
  • PROTONIX Delayed-Release Tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Important Safety Information
  • In clinical trials, the most frequently reported adverse events with PROTONIX Delayed-Release Tablets were headache, diarrhea, and flatulence. Symptomatic response to therapy does not preclude the presence of gastric malignancy. PROTONIX is contraindicated in patients with known hypersensitivity to any component of the formulation. Patients treated with PPIs and warfarin concomitantly should be monitored for increases in INR and prothrombin time.

Please see Prescribing Information

PROTONIX I.V.

Indications
  • PROTONIX I.V. for Injection is indicated for short-term treatment (7 to 10 days) of patients with GERD and a history of erosive esophagitis.
  • PROTONIX I.V. for Injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison syndrome (ZES) or other neoplastic conditions.
Important Safety Information
  • In clinical trials, the most frequently reported adverse events with PROTONIX I.V. were injection site reactions (including thrombophlebitis and abscess), headache, diarrhea, nausea, and dyspepsia. PROTONIX I.V. is contraindicated in patients with known hypersensitivity to any component of the formulation. Anaphylaxis has been reported. As with any other intravenous product containing EDTA, zinc supplementation should be considered in patients treated with PROTONIX I.V. who are prone to zinc deficiency.

Please see Prescribing Information

References

  1. Data on file, Wyeth Pharmaceuticals Inc.
  2. Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther. 2004;20:567-575.
  3. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000;118:696-704.

Under license from Nycomed GmbH, D78467 Konstanz, Germany.

Protonix.com PROTONIX 40 mg - Full Prescribing Information PROTONIX I.V. - Full Prescribing Information

PROTONIX Site Map

120805-01   July 2007